Pharmaceutical sector is, by far, one of the biggest wealth creators in 2020, it was the first sector to bounce back after the lows in March and the run is more or less continued. What after the mammoth gains that pharma index and largecap pharma stocks have seen? Prakash Agarwal, Pharma Analyst at Axis Capital, who tracks this space, discussed this on CNBC-TV18.
Recommended Articles
View All
Budget 2023: From improved GST structure to inverted duty reforms, the EV sector want a mega growth push
Jan 31, 2023 IST3 Min(s) Read
India's Economic Survey shifts the narrative to 'quality of life'
Jan 31, 2023 IST3 Min(s) Read
Budget 2023: Prioritising defence and innovation
Jan 31, 2023 IST4 Min(s) Read
Budget 2023—ESOP tax incentives drive start-up growth
Jan 31, 2023 IST6 Min(s) Read
The big rerating has happened in pharmaceutical sector. We remain positive on the sector but we also are selective on stocks, he said.
We are looking at Cadila Healthcare, Divi’s Laboratories, Biocon as our top picks followed by Dr Reddy’s Laboratories (DRL) and Cipla, he added.
We have a reduced rating on Sun Pharmaceuticals and Syngene, Agarwal mentioned.
Watch video for more